disease-modifying antirheumatic agent (DMARD)
Jump to navigation
Jump to search
More general terms
More specific terms
- abatacept (Orencia)
- apremilast (Otezla)
- auranofin [gold] (Ridaura)
- aurothioglucose [gold] (Solganal)
- azathioprine (Azanin, Imuran, Imurel)
- baricitinib (Olumiant)
- cyclophosphamide (Cytoxan, Neosar, Procytox {Canadian}) [CPM, CTX, CYT, NSC 26271]
- cyclosporin A (Sandimmune, Neoral [CsA])
- dapsone (Avlosulfon)
- gold sodium thiomalate; aurothiomalate (Myochrysine, Chrysothios)
- hydroxychloroquine (Plaquenil)
- leflunomide; teriflunomide (Arava)
- methotrexate (Rheumatrex, MTX)
- minocycline (Minocin, Solodyn)
- mycophenolate (Cellcept, Myfortic)
- oclacitinib maleate (Apoquel)
- penicillamine (Cuprimine, Depen)
- sulfasalazine (SSZ, Azulfidine, SAS)
- tocilizumab; atlizumab (Actemra, RoActemra)
- tofacitinib (Xeljanz)
References
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 16 American College of Physicians, Philadelphia 2012
- ↑ Donahue KE, Gartlehner G, Jonas DE et al Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med. 2008 Jan 15;148(2):124-34 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18025440